

**SCI-CONF.COM.UA**

# **SCIENCE, TECHNOLOGY AND GLOBAL CHALLENGES**



**PROCEEDINGS OF IV INTERNATIONAL  
SCIENTIFIC AND PRACTICAL CONFERENCE  
DECEMBER 4-6, 2025**

**TOKYO  
2025**

## TABLE OF CONTENTS

### AGRICULTURAL SCIENCES

1. *Копилова О. І., Любицька Д. М.* 16  
БІОЛОГІЧНІ ХАРАКТЕРИСТИКИ ТА ФІЗІОЛОГО-  
МОРФОЛОГІЧНІ ОСОБЛИВОСТІ КАРТОПЛІ
2. *Макарова Д. Г., Кузьминець О. М., Василенко В. І.* 20  
МОНІТОРИНГ ПОГОДНИХ УМОВ І УРОЖАЙНІСТЬ  
КІСТОЧКОВИХ КУЛЬТУР У ЗАХІДНОМУ ЛІСОСТЕПУ  
УКРАЇНИ

### BIOLOGICAL SCIENCES

3. *Hryhorieva V., Kotova O.* 29  
FEATURES OF TRAINING FUTURE MATHEMATICS TEACHERS  
FOR PROFESSIONAL ACTIVITY IN THE CONDITIONS OF  
FORCED DISTANCE LEARNING
4. *Корендевич К. Ю., Шелюк Ю. С.* 35  
ОТРУЙНІ ТА КАРАНТИННІ РОСЛИНИ У ФЛОРИ  
М. ЖИТОМИРА

### MEDICAL SCIENCES

5. *Avdusenko M. V.* 38  
PHENOTYPICAL FEATURES OF CONNECTIVE TISSUE  
DYSPLASIA IN ADOLESCENTS
6. *Nechytaylo L. Ya., Uhryniuk I. I., Liuklian S. V.* 41  
ENVIRONMENTAL POLLUTION BY HEAVY METALS DURING  
MILITARY CONFLICTS AND THEIR IMPACT ON THE HUMAN  
ORGANISM
7. *Pryimak D., Myroshnychenko D., Petiunin O.* 46  
CONSERVATIVE TREATMENT OF ADHESIVE INTESTINAL  
OBSTRUCTION: EFFECTIVENESS OF NON-SURGICAL  
METHODS IN AVOIDING SURGICAL INTERVENTION
8. *Semenenko S. B., Slobodian K. V., Dzhuriak V. S., Chernei N. Ya., Fedorenko E. Yu.* 51  
BLOWING STRESS ON PEOPLE'S HEALTH (LITERATURE  
REVIEW)
9. *Shatov P. O., Savelieva N. M.* 56  
ANALYSIS OF THE EFFECT OF DOMESTIC RINSING ON  
MICROBIAL CONTAMINATION OF ORAL PIERCINGS MADE  
FROM VARIOUS DENTAL MATERIALS
10. *Siusiuka V., Kyrychenko M.* 61  
ASSESSMENT OF THE EFFECTIVENESS OF PROPHYLACTIC  
APPROACHES FOR PREVENTING HYPERTENSIVE DISORDERS  
OF PREGNANCY IN HIGH-RISK GROUPS

**ASSESSMENT OF THE EFFECTIVENESS OF PROPHYLACTIC  
APPROACHES FOR PREVENTING HYPERTENSIVE DISORDERS OF  
PREGNANCY IN HIGH-RISK GROUPS**

**Siusiuka Volodymyr**

MD, DSc, Professor, Head of the Department of Obstetrics and Gynecology

**Kyrychenko Mykhailo**

MD, Assistant of the Department of Obstetrics and Gynecology

Zaporizhzhia State Medical and Pharmaceutical University

Zaporizhzhia, Ukraine

**Abstract:** This study analyzed the clinical and anamnestic characteristics and the course of pregnancy in 64 women at high risk for hypertensive disorders of pregnancy, who were allocated to groups receiving either combined or standard prophylaxis. The frequency of obstetric complications was assessed, alongside the effectiveness of the prophylactic approaches and their impact on gestational outcomes.

**Keywords:** pregnancy; hypertensive disorders of pregnancy; preeclampsia; prevention; clinical characteristics; high-risk group; obstetric complications.

**Introduction**

Hypertensive disorders of pregnancy (HDP) remain one of the leading causes of maternal and perinatal morbidity and mortality worldwide, despite continuous improvements in obstetric care and increased awareness of their long-term consequences for both mother and child [1-3]. The most clinically significant form of HDP is preeclampsia, characterized by endothelial dysfunction, systemic inflammation, impaired vascular adaptation, and a high incidence of adverse perinatal outcomes [1-3]. Oxidative stress and disturbances in placental remodeling play key roles in the pathogenesis of these conditions, ultimately leading to dysfunction of the feto-placental unit [4-7].

Physiological pregnancy is accompanied by profound cardiovascular, metabolic, and immunological adaptations, the adequacy of which largely depends on the balance between the generation of reactive oxygen and nitrogen species, the effectiveness of antioxidant defenses, and sufficient bioavailability of nitric oxide (NO) [8-10]. Disruption of redox homeostasis results in excessive accumulation of free radicals, damage to cellular structures, activation of pro-inflammatory cascades, and progression of endothelial dysfunction [6, 9-11]. The placenta, as an organ with high metabolic activity, is particularly vulnerable to oxidative imbalance: inadequate trophoblastic invasion, incomplete remodeling of the spiral arteries, and intermittent perfusion of the intervillous space lead to episodes of hypoxia-reoxygenation, which exacerbate reperfusion injury and contribute to the development of clinical manifestations of HDP and fetal growth restriction [7, 12-15].

Alterations in the redox state and NO-dependent pathways may occur early in gestation, long before the clinical onset of hypertension. This creates a critical “window of opportunity” for early prophylactic intervention in women at high risk for developing HDP [5, 9, 16]. Contemporary preventive strategies increasingly focus on targeting the early mechanisms of pathogenesis, particularly in correcting endothelial dysfunction. L-arginine, the principal substrate for NO synthesis, is considered a promising agent for improving vasodilation and uteroplacental perfusion. Evidence from randomized trials and meta-analyses suggests a potential reduction in the risk of preeclampsia and fetal growth restriction in high-risk populations, although the level of evidence remains moderate [11-13]. In parallel, antioxidant strategies aimed at enhancing placental resistance to oxidative injury continue to be investigated. Existing systematic and network meta-analyses demonstrate a potential beneficial effect of such interventions on the risk of preeclampsia and/or gestational hypertension; however, substantial heterogeneity among studies limits the ability to formulate definitive recommendations [4, 7, 14, 15]. In this context, combining agents that concurrently enhance NO-dependent mechanisms and the organism’s antioxidant capacity appears biologically plausible and may more effectively prevent early disturbances in vascular regulation.

**Objective:** To evaluate the effectiveness of prophylactic approaches for preventing hypertensive disorders of pregnancy in high-risk women and to assess their impact on delivery outcomes.

### **Materials and Methods**

The study was conducted at the clinical site of the Municipal Non-Commercial Enterprise “Regional Perinatal Center” of the Zaporizhzhia Regional Council. A total of 64 pregnant women in their first trimester, who met the criteria for high risk of developing hypertensive disorders of pregnancy according to current clinical guidelines of the Ministry of Health of Ukraine, were enrolled. Following an initial clinical assessment, all participants were randomized by simple random sampling into two equal groups of 32 women each: C1 and C2.

Group C1 received the standard prophylactic regimen, which included acetylsalicylic acid at a dose of 150 mg/day from 12 to 36 weeks of gestation and calcium at a dose of 1–2 g/day starting from 16 weeks, along with an additional combined prophylactic therapy. The combined regimen consisted of L-arginine aspartate (200 mg/mL, 5 mL three times daily for 14 days) and a micronutrient complex with antioxidant and endothelioprotective properties (folic acid 400 µg, cholecalciferol 5 µg, docosahexaenoic acid 200 mg, vitamin E 12 mg, potassium iodide 150 µg once daily).

Group C2 received only the standard prophylaxis recommended by the Ministry of Health of Ukraine.

The clinical assessment included evaluation of clinical data, obstetric-gynecological history, and somatic history. All examinations adhered to the requirements of the national regulatory documents of the Ministry of Health of Ukraine, including the current medical care standard “Normal Pregnancy” (Order No. 1437, dated August 9, 2022) and the Unified Clinical Protocol “Hypertensive Disorders of Pregnancy” (Order No. 151, dated January 24, 2022).

Evaluation of the fetoplacental unit was performed using standard ultrasound fetometry and Doppler studies. Doppler indices of vascular resistance were interpreted in accordance with the percentile ranges defined by the Fetal Medicine

Foundation.

## **Results**

The comparative sample included 64 pregnant women who were statistically homogeneous across the main clinical parameters ( $p>0.05$ ). The mean age of the participants was  $31.09 \pm 5.45$  years, with a median of 30.5 [27-36] years. The distribution of occupational categories was balanced, with no statistically significant differences between the groups ( $p>0.05$ ). Most participants were office employees (42.19%) or healthcare workers (20.31%), while homemakers accounted for 18.75% and entrepreneurs for 14.06%. Students and manual workers were rare. Urban residents predominated (78.1%), significantly exceeding the proportion of women from rural areas (21.9%;  $p<0.05$ ); however, the urban-to-rural ratio did not differ between groups C1 and C2 ( $p>0.05$ ).

Marital status was similarly distributed: 76.56% of women were married, whereas 23.44% were unmarried. Parity characteristics were balanced: 39.1% of pregnancies were first pregnancies, while 60.9% were subsequent. First births accounted for 56.2% and repeated births for 43.8%. Previous medical abortions were reported by 18.8% of women, spontaneous miscarriages by 9.4%, and preterm birth in history by 6.3%. Overall, the cumulative frequency of pregnancy losses was low (16 medical and 10 spontaneous abortions).

Extragenital pathology (EGP) was documented in 84.36% of the women. Metabolic disorders were most common, including overweight (76.6%) and obesity (25.0%). Ophthalmologic conditions were represented mainly by myopia (15.6%), with isolated cases of retinal angiodystonia (1.6%) and complex myopic astigmatism (3.1%). Somatoform autonomic dysfunction was frequent (43.8%). Among cardiovascular disorders, mitral valve prolapse (14.1%) and varicose disease of the lower limbs (15.6%) were most prevalent. Other EGP included chronic pyelonephritis (10.9%), nontoxic goiter and hypothyroidism (15.6%), dorsopathies (10.9%), as well as isolated cases of urolithiasis (1.6%), chronic cholecystitis (3.1%), and chronic cytomegalovirus infection (9.4%).

Gynecological disorders were recorded in 39.1% of participants. Cervical



erosion/ectopy was most frequent (31.3%), followed by mild cervical dysplasia (10.9%) and ovarian cysts (9.4%). Isolated cases of PCOS, ectopic pregnancy, and uterine scarring were observed. Most women (90.6%) had regular menstrual cycles.

Among high-risk factors, the most common were a history of HDP (35.9%) and an adverse obstetric history in the participant's mother (18.8%). Moderate risk factors included age over 35 years (37.5%), BMI >30 kg/m<sup>2</sup> (25.0%), primigravidity (32.8%), and a family history of hypertension (28.1%). The prevalence of individual risk factors did not differ between C1 and C2 ( $p>0.05$ ).

The incidence of HDP was substantially lower in the combined prophylaxis group. In C1, HDP developed in 5 of 32 women (15.6%) – 2 cases of moderate preeclampsia and 3 cases of gestational hypertension; no severe preeclampsia was recorded. In C2, HDP occurred in 12 of 32 participants (37.5%), including 5 cases of moderate, 1 case of severe preeclampsia, and 6 cases of gestational hypertension. Accordingly, the proportion of women without HDP was 84.4% in C1 versus 62.5% in C2.

Prepregnancy and third-trimester body weight and BMI were comparable between groups ( $p>0.05$ ). The mean prepregnancy BMI was 22.17 kg/m<sup>2</sup> in C1 and 22.92 kg/m<sup>2</sup> in C2; in the third trimester, 27.40 and 27.28 kg/m<sup>2</sup>, respectively.

A wide spectrum of gestational complications, typical for high-risk HDP populations, was observed. The most frequent condition was maternal anemia: 53.1% in C1 and 62.5% in C2. Threatened miscarriage before 22 weeks occurred in 21.9% of C1 and 37.5% of C2; cervical insufficiency in 6.3% and 12.5%, respectively. Threatened preterm labor (false contractions before 37 weeks) was observed in more than two-thirds of the entire cohort. More severe complications – including preterm premature rupture of membranes and placental abruption – were documented only in the standard prophylaxis group. However, the overall frequency of gestational complications did not differ significantly between groups ( $p>0.05$ ).

Third-trimester Doppler findings showed normal blood flow in 68.8% of women in C1 and 59.4% in C2. Terminal hemodynamic disturbances (absent or reversed end-diastolic flow) were found in 28.1% of C1 and 34.4% of C2; one case of

reversed flow was recorded in C2. Although the difference was not statistically significant ( $p>0.05$ ), a trend toward more severe hemodynamic impairment was noted in C2. In both groups, Doppler abnormalities predominantly emerged in the third trimester.

Abnormalities of the amniotic fluid index were sporadic, with similar frequencies of polyhydramnios and oligohydramnios in both groups ( $p>0.05$ ). Most women had normal amniotic fluid volumes.

Fetal growth restriction was more frequently diagnosed in C2: 2 cases (6.25%) in C1 versus 5 cases (15.6%) in C2.

Most women in both groups delivered at term, although the mean gestational age at delivery was significantly higher in C1:  $38.5 \pm 1.1$  weeks (median 39 weeks) versus  $37.97 \pm 1.2$  weeks (median 38 weeks) in C2 ( $p<0.05$ ). Preterm delivery ( $<37$  weeks) occurred in 6.25% of C2, whereas in C1 pregnancies typically concluded between 38 and 40 weeks.

Vaginal delivery predominated, though the rate of cesarean section was higher in C2 (40.6% vs. 21.9% in C1). Despite the lack of statistical significance ( $p>0.05$ ), the structure of indications differed. In C1, the leading indication was previous uterine scar (4 cases, 57.1%), primarily requiring planned procedures. In C2, indications were more heterogeneous, including maternal factors (uterine scar 7.7%, clinically narrow pelvis 7.7%) and fetal factors (breech presentation 30.8%, fetal distress in the first stage of labor 15.4%, signs of fetal hypoxia 7.7%, placental abruption 7.7%).

Among women delivering vaginally, the overall frequency of intrapartum complications was moderate and similar between groups ( $p>0.05$ ). In C1, the most common complications were fetal distress in the first (4.0%) and second stages (4.0%), labor abnormalities (4.0%), and shoulder dystocia (4.0%). In C2, fetal distress in the first stage (10.5%), placental abruption (5.3%), and clinically narrow pelvis (5.3%) predominated.

Mean obstetric blood loss remained within physiological limits in both groups. For vaginal deliveries, blood loss was 200 [200-250] mL in C1 and 250



[200-250] mL in C2. For cesarean sections, the median blood loss was 600 [600-600] mL in both groups. No statistically significant differences were observed ( $p>0.05$ ).

### **Conclusions**

1. The findings of this study indicate a high prevalence of extragenital pathology (84.36%) among pregnant women at high risk for hypertensive disorders, with metabolic disorders, somatoform autonomic dysfunction, and varicose disease being the most common. This pattern reflects the typical polymorbidity observed in high-risk populations for hypertensive disorders of pregnancy.

2. Combined prophylaxis with L-arginine and a micronutrient complex was associated with a lower incidence of hypertensive disorders of pregnancy – 15.6% compared to 37.5% in the group receiving standard prophylaxis – and with the absence of severe preeclampsia.

3. Indicators of fetal well-being demonstrated a trend toward better hemodynamic compensation in the combined prophylaxis group, with fewer cases of severe blood flow abnormalities and a lower frequency of fetal growth restriction.

4. Obstetric outcomes were more favorable in the group of pregnant women receiving combined prophylaxis, which contributed to a reduction in the rate of emergency cesarean delivery.

### **REFERENCES**

1. Dimitriadis, E., Rolnik, D. L., Zhou, W., Estrada-Gutierrez, G., Koga, K., Francisco, R. P. V., et al. (2023). *Pre-eclampsia. Nature Reviews Disease Primers*, 9(1), 8. <https://doi.org/10.1038/s41572-023-00417-6>
2. Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019). *Pre-eclampsia: Pathophysiology and clinical implications. BMJ*, 366, 12381. <https://doi.org/10.1136/bmj.12381>
3. Rana, S., Lemoine, E., Granger, J. P., & Karumanchi, S. A. (2019). *Preeclampsia: Pathophysiology, challenges, and perspectives. Circulation Research*, 124(7), 1094-1112. <https://doi.org/10.1161/CIRCRESAHA.118.313276>
4. Afrose, D., Alfonso-Sánchez, S., & McClements, L. (2025). *Targeting*

*oxidative stress in preeclampsia. Hypertension in Pregnancy, 44(1), 2445556.*  
<https://doi.org/10.1080/10641955.2024.2445556>

5. Negre-Salvayre, A., Swiader, A., Salvayre, R., & Guerby, P. (2022). *Oxidative stress, lipid peroxidation and premature placental senescence in preeclampsia. Archives of Biochemistry and Biophysics, 730, 109416.*  
<https://doi.org/10.1016/j.abb.2022.109416>

6. Cuffe, J. S., Xu, Z. C., & Perkins, A. V. (2017). *Biomarkers of oxidative stress in pregnancy complications. Biomarkers in Medicine, 11(3), 295-306.*  
<https://doi.org/10.2217/bmm-2016-0250>

7. Schoots, M. H., Gordijn, S. J., Scherjon, S. A., van Goor, H., & Hillebrands, J. L. (2018). *Oxidative stress in placental pathology. Placenta, 69, 153-161.* <https://doi.org/10.1016/j.placenta.2018.03.003>

8. Granger, D. N., & Kvietys, P. R. (2015). *Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biology, 6, 524-551.*  
<https://doi.org/10.1016/j.redox.2015.08.020>

9. Joo, E. H., Kim, Y. R., Kim, N., Jung, J. E., Han, S. H., & Cho, H. Y. (2021). *Effect of endogenous and exogenic oxidative stress triggers on adverse pregnancy outcomes: Preeclampsia, fetal growth restriction, gestational diabetes mellitus and preterm birth. International Journal of Molecular Sciences, 22(18), 10122.* <https://doi.org/10.3390/ijms221810122>

10. Jovandaric, M. Z., Babic, S., Raus, M., & Medjo, B. (2023). *The importance of metabolic and environmental factors in the occurrence of oxidative stress during pregnancy. International Journal of Molecular Sciences, 24(15), 11964.*  
<https://doi.org/10.3390/ijms241511964>

11. Makama, M., Nyan, M., Adeyemi, A., Olayemi, O., Balogun, S., Bello, B., et al. (2025). *L-Arginine and L-Citrulline for prevention and treatment of hypertensive disorders of pregnancy: Systematic review and meta-analysis of randomized controlled trials. BJOG: An International Journal of Obstetrics & Gynaecology, 132(2), 199-211.* <https://doi.org/10.1111/1471-0528.17854>

12. Naderipour, F., Soleimani, Z., Akbari, N., Samimi, M., & Rahimi, H. R.

(2024). *Efficacy of L-arginine for preventing preeclampsia and intrauterine growth restriction: Systematic review and meta-analysis. International Journal of Fertility & Sterility*. Advance online publication. <https://doi.org/10.22074/IJFS.2024.579502>

13. Vadillo-Ortega, F., Perichart-Perera, O., Espino, S., Basurto, L., Mateo, T., Sanchez, S. E., et al. (2011). *Effect of supplementation with L-arginine during pregnancy on the risk of pre-eclampsia: Randomised controlled trial. BMJ*, 342, d2901. <https://doi.org/10.1136/bmj.d2901>

14. Alves, P. R. M. M., Costa, R. F., Souza, R. T., Macedo, I. C., Bueno, L. M., Mota, L., et al. (2023). *The role played by oral antioxidant therapies in preventing and treating preeclampsia: Systematic review and meta-analysis. Pregnancy Hypertension*, 33, 30-41. <https://doi.org/10.1016/j.preghy.2023.01.007>

15. Liabsuetrakul, T., Tanprasertkul, C., Ruengorn, C., Rattanachaiyanont, M., Techatraisak, K., & Tongsong, T. (2022). *Antioxidants and risk of preeclampsia/gestational hypertension among high-risk women: Network meta-analysis. BMC Pregnancy and Childbirth*, 22(1), 746. <https://doi.org/10.1186/s12884-022-05146-0>

16. Kalogeris, T., Baines, C. P., Krenz, M., & Korthuis, R. J. (2016). *Ischemia/Reperfusion. Comprehensive Physiology*, 7(1), 113-170. <https://doi.org/10.1002/cphy.c160006>